IBTROZI® (taletrectinib)
ROS1-positive non-small cell lung cancer
ApprovedCommercial Launch
Key Facts
Indication
ROS1-positive non-small cell lung cancer
Phase
Approved
Status
Commercial Launch
Company
About Nippon Kayaku
A century-old Japanese diversified chemical company with a growing oncology focus, recently launching IBTROZI® (taletrectinib) for ROS1-positive NSCLC.
View full company profileTherapeutic Areas
Other ROS1-positive non-small cell lung cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Taletrectinib | Eisai | Regulatory Review |